Immunosuppressive therapy in lupus‐ and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty‐three cases
Open Access
- 31 January 2008
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (2), 521-531
- https://doi.org/10.1002/art.23303
Abstract
Objective To describe the response to first-line immunosuppressive therapy with or without pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD). Methods Twenty-three consecutive patients with SLE- or MCTD-associated PAH treated with first-line immunosuppressive therapy either alone (n = 16) or in combination with pulmonary vasodilators (n = 7) were evaluated according to clinical and hemodynamic criteria before and after immunosuppressive therapy. Responders were defined as patients in New York Heart Association (NYHA) functional class I or II with hemodynamic improvement after the last pulse of cyclophosphamide. Results Among the 16 patients treated with first-line immunosuppressive therapy alone, 8 (50%) were responders. These patients had a significantly improved NYHA functional class, 6-minute walking distance, and mean pulmonary artery pressure. Patients in NYHA functional class I or II and/or a cardiac index >3.1 liters/minute/m2 at baseline were more likely to benefit from immunosuppressive therapy. Six of the 8 nonresponders subsequently improved with pulmonary vasodilators. Among the 7 patients who were initially treated with immunosuppressive therapy and pulmonary vasodilators, 4 (57.1%) were responders. Conclusion PAH associated with SLE or MCTD may respond to a treatment combining cyclophosphamide and glucocorticoids. Patients who could benefit from this immunosuppressive therapy could be those who have less severe disease at baseline. For patients with more severe disease, pulmonary vasodilators should be started, possibly in combination with immunosuppressants. In any case, clinical and hemodynamic evaluations are mandatory to monitor the response and adapt the treatment. These retrospective and uncontrolled data need to be confirmed by randomized controlled trials.Keywords
This publication has 28 references indexed in Scilit:
- Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial HypertensionCirculation, 2005
- Maintenance Therapies for Proliferative Lupus Nephritis: Mycophenolate Mofetil, Azathioprine and Intravenous CyclophosphamideLupus, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Clinical classification of pulmonary hypertensionJournal of the American College of Cardiology, 2004
- Inflammation in pulmonary arterial hypertensionEuropean Respiratory Journal, 2003
- Pulmonary Hypertension in the Collagen Vascular DiseasesSeminars in Respiratory and Critical Care Medicine, 2003
- Severe Pulmonary Hypertension in a Patient with Systemic Lupus Erythematosus and Minimal Lupus Activity.Internal Medicine, 2002
- Improvement of severe pulmonary hypertension in a patient with SLE.Annals Of The Rheumatic Diseases, 1996
- Pulmonary Hypertension in Systemic Lupus Erythematosus: A Report of an Autopsied Case.Internal Medicine, 1994
- Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus ErythematosusNew England Journal of Medicine, 1988